Spondyloarthritis & psoriatic arthritis
The value of correctly diagnosing axial spondyloarthritis for patients and society
Authors' conclusion
Correct diagnosis of axSpA results in substantial health and cost benefits for patients and society. Not requiring IBP as mandatory for diagnosis of axSpA (algorithm M2) provides more value and would be preferable.
Study context
- Population
- Patients with low back pain referred to a rheumatologist (model using data from SPACE and other cohorts)
- Comparison
- Diagnostic algorithms for axSpA: Berlin vs Modification 1 vs Modification 2, and perfect diagnosis
- Outcome
- Health (QALYs) and costs (healthcare consumption and work productivity losses) per patient
- Follow-up
- 60-year horizon
Methodological detailsdecision-tree combined with state-transition model, 60-year horizon, societal perspective
- Decision-tree combined with state-transition model
- 60-year horizon
- Societal perspective
Main finding
As reported in the abstract
| Group | Value | Costs |
|---|---|---|
| M2 | 24.23 QALYs | €157,469 |
| BER | 23.96 QALYs | €159,423 |
| M1 | 24.15 QALYs | €158,417 |
Value
M224.23 QALYs
BER23.96 QALYs
M124.15 QALYs
Costs
M2€157,469
BER€159,423
M1€158,417
- Per correctly diagnosed axSpA patient, QALYs gained (societal perspective)
- up to 4.7
- Per correctly diagnosed axSpA patient, costs saved (societal perspective)
- €60,000
Further findings
Hypothetical improvements in M2 sensitivity vs specificity
- Improvements in M2 sensitivity gave slightly more value than improvements in specificity
Value of perfect diagnosis
- Perfect diagnosis can cost this much per patient and still provide enough value
- €7,500
Original publication
The value of correctly diagnosing axial spondyloarthritis for patients and society. Semin Arthritis Rheum. Published 5 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →